Cargando…

Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer

Canine mammary cancer (CMC), similar to human breast cancer (HBC) in many aspects, is the most common neoplasm associated with significant mortality in female dogs. Due to the limited therapy options, biomarkers are highly desirable for early clinical diagnosis or cancer progression monitoring. Sinc...

Descripción completa

Detalles Bibliográficos
Autores principales: Petroušková, Patrícia, Hudáková, Nikola, Maloveská, Marcela, Humeník, Filip, Cizkova, Dasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032658/
https://www.ncbi.nlm.nih.gov/pubmed/35455015
http://dx.doi.org/10.3390/life12040524
_version_ 1784692698707394560
author Petroušková, Patrícia
Hudáková, Nikola
Maloveská, Marcela
Humeník, Filip
Cizkova, Dasa
author_facet Petroušková, Patrícia
Hudáková, Nikola
Maloveská, Marcela
Humeník, Filip
Cizkova, Dasa
author_sort Petroušková, Patrícia
collection PubMed
description Canine mammary cancer (CMC), similar to human breast cancer (HBC) in many aspects, is the most common neoplasm associated with significant mortality in female dogs. Due to the limited therapy options, biomarkers are highly desirable for early clinical diagnosis or cancer progression monitoring. Since the discovery of microRNAs (miRNAs or miRs) as post-transcriptional gene regulators, they have become attractive biomarkers in oncological research. Except for intracellular miRNAs and cell-free miRNAs, exosome-derived miRNAs (exomiRs) have drawn much attention in recent years as biomarkers for cancer detection. Analysis of exosomes represents a non-invasive, pain-free, time- and money-saving alternative to conventional tissue biopsy. The purpose of this review is to provide a summary of miRNAs that come from non-exosomal sources (canine mammary tumor, mammary tumor cell lines or canine blood serum) and from exosomes as promising biomarkers of CMC based on the current literature. As is discussed, some of the miRNAs postulated as diagnostic or prognostic biomarkers in CMC were also altered in HBC (such as miR-21, miR-29b, miR-141, miR-429, miR-200c, miR-497, miR-210, miR-96, miR-18a, miR19b, miR-20b, miR-93, miR-101, miR-105a, miR-130a, miR-200c, miR-340, miR-486), which may be considered as potential disease-specific biomarkers in both CMC and HBC.
format Online
Article
Text
id pubmed-9032658
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90326582022-04-23 Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer Petroušková, Patrícia Hudáková, Nikola Maloveská, Marcela Humeník, Filip Cizkova, Dasa Life (Basel) Review Canine mammary cancer (CMC), similar to human breast cancer (HBC) in many aspects, is the most common neoplasm associated with significant mortality in female dogs. Due to the limited therapy options, biomarkers are highly desirable for early clinical diagnosis or cancer progression monitoring. Since the discovery of microRNAs (miRNAs or miRs) as post-transcriptional gene regulators, they have become attractive biomarkers in oncological research. Except for intracellular miRNAs and cell-free miRNAs, exosome-derived miRNAs (exomiRs) have drawn much attention in recent years as biomarkers for cancer detection. Analysis of exosomes represents a non-invasive, pain-free, time- and money-saving alternative to conventional tissue biopsy. The purpose of this review is to provide a summary of miRNAs that come from non-exosomal sources (canine mammary tumor, mammary tumor cell lines or canine blood serum) and from exosomes as promising biomarkers of CMC based on the current literature. As is discussed, some of the miRNAs postulated as diagnostic or prognostic biomarkers in CMC were also altered in HBC (such as miR-21, miR-29b, miR-141, miR-429, miR-200c, miR-497, miR-210, miR-96, miR-18a, miR19b, miR-20b, miR-93, miR-101, miR-105a, miR-130a, miR-200c, miR-340, miR-486), which may be considered as potential disease-specific biomarkers in both CMC and HBC. MDPI 2022-04-01 /pmc/articles/PMC9032658/ /pubmed/35455015 http://dx.doi.org/10.3390/life12040524 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Petroušková, Patrícia
Hudáková, Nikola
Maloveská, Marcela
Humeník, Filip
Cizkova, Dasa
Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer
title Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer
title_full Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer
title_fullStr Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer
title_full_unstemmed Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer
title_short Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer
title_sort non-exosomal and exosome-derived mirnas as promising biomarkers in canine mammary cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032658/
https://www.ncbi.nlm.nih.gov/pubmed/35455015
http://dx.doi.org/10.3390/life12040524
work_keys_str_mv AT petrouskovapatricia nonexosomalandexosomederivedmirnasaspromisingbiomarkersincaninemammarycancer
AT hudakovanikola nonexosomalandexosomederivedmirnasaspromisingbiomarkersincaninemammarycancer
AT maloveskamarcela nonexosomalandexosomederivedmirnasaspromisingbiomarkersincaninemammarycancer
AT humenikfilip nonexosomalandexosomederivedmirnasaspromisingbiomarkersincaninemammarycancer
AT cizkovadasa nonexosomalandexosomederivedmirnasaspromisingbiomarkersincaninemammarycancer